CURHAN GREGORY S 4
4 · Serina Therapeutics, Inc. · Filed May 26, 2026
Research Summary
AI-generated summary of this filing
Serina (SER) CFO Gregory Curhan Receives 123,019-Share Award
What Happened Gregory S. Curhan, Chief Financial Officer of Serina Therapeutics (SER), was granted 123,019 derivative shares on 2026-05-21. The grant is recorded at $0.00 per share (an award/derivative instrument rather than an open‑market purchase), so no cash was exchanged at grant.
Key Details
- Transaction date: 2026-05-21; Form 4 filed: 2026-05-26.
- Transaction type/code: Award/Grant (derivative) — 123,019 shares at $0.00.
- Reported consideration: $0.00 (award/derivative instrument).
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Footnote (vesting): 12/48ths of the shares vest twelve months after the Vesting Commencement Date, then 1/48th vests each month thereafter until fully vested.
- No 10b5-1 plan, tax‑withholding, or cashless sale noted in the provided details.
Context This was a compensation award (likely stock options or restricted stock units subject to the stated vesting schedule), not an open‑market purchase or sale. Such grants are common for executive compensation and do not by themselves indicate immediate buying or selling of shares; vesting and any later sales would be reported in subsequent filings.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-05-21+123,019→ 123,019 totalExercise: $1.89Exp: 2036-05-21→ Common Stock (123,019 underlying)
Footnotes (1)
- [F1]Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested.